Product Design, Manufacturing & Innovation Resources

أحدث المنشورات وبراءات الاختراع في علم الأورام الجزيئي

منشورات وبراءات اختراع علم الأورام الجزيئي

Tip: further to the selection below, you can search and filter our 2 entire databases:

> free publications search tool < حسب المؤلف، أو الموضوع، أو الكلمات المفتاحية، أو التاريخ، أو المجلة.

> free patents search tool < للحصول على براءات اختراع باللغة الإنجليزية من مكتب براءات الاختراع الأوروبي.

علم الأورام الجزيئي
يستفيد علم الأورام الجزيئي من التقنيات المتقدمة لابتكار تشخيص وعلاج السرطان من خلال الرؤى الجينية والكيميائية الحيوية.

يُعنى علم الأورام الجزيئي بدراسة التغيرات الجينية والوراثية والكيميائية الحيوية التي تُحفز بدء السرطان وتطوره ومقاومته للعلاج. يدمج هذا المجال تقنيات التسلسل عالي الإنتاجية والتشخيص الجزيئي والعلاجات الموجهة لتوضيح المسارات السرطانية، وتعطيل جينات كبت الورم، وتفاعلات البيئة الدقيقة للورم. تُعيد التطورات في التنميط الجزيئي واكتشاف المؤشرات الحيوية والطب الدقيق تعريف تصنيف السرطان واستراتيجيات علاجه. يُقدم هذا التقرير أحدث المنشورات المُحكّمة والابتكارات الحاصلة على براءات اختراع، والتي تعكس أحدث الأبحاث في مجال الجينات السرطانية، ونقل الإشارات، والخلايا الجذعية السرطانية، وتعديل المناعة، وتقنيات التصوير الجزيئي الأساسية لعلم الأورام الانتقالي والتطبيقات السريرية.

This is our latest selection of worldwide publications and patents in english on Molecular Oncology, between many scientific online journals, classified and focused on oncogene, tumor suppresso, signal transduction pathway, cancer genomic, epigenetics in cancer, molecular biomarker, targeted cancer therapy, cancer cell signaling, DNA mutation, microRNAs in oncology, cancer stem cell, apoptosis regulation, tumor microenvironment, cancer immunotherapy, gene expression profil, chromosomal aberration, molecular diagnostic, cancer proteomic, oncogenic pathway, cancer metastasis, molecular mechanisms of carcinogenesis, tumor heterogeneity, cancer epigenomic, oncogenic viruse, molecular targeted drug, cancer transcriptomics, DNA repair mechanism, cancer pharmacogenomic and cancer molecular patholog.

Eutrema japonica leaf alcohol extract and use thereof in treatment of cancer stem cell-related cancer

Patent published on the 2026-10-01 in WO under Ref WO2026200822 by TAIWAN FLOWER BIOTECHNOLOGY CO LTD [CN] (Wang Lu-hai [cn], Huang A-chih [cn], Huang Shi-jie [cn], Lee Yu Ting [cn])

Abstract: Disclosed is use of a pharmaceutical composition in the manufacture of a medicament for treating a cancer stem cell-related cancer, inhibiting the recurrence or metastasis of cancer stem cells after cancer tumor resection, or inhibiting tumor-associated angiogenesis. The pharmaceutical composition comprises an Eutrema japonica leaf alcohol extract. The cancer stem cell-related cancer comprises triple-negative breast cancer, ovarian cancer, prostate cancer, lung cancer, or oral cancer.[...]


Our summary: Eutrema japonica leaf alcohol extract is used in a pharmaceutical composition to treat cancer stem cell-related cancers. It aims to inhibit recurrence or metastasis of cancer stem cells post-tumor resection. The extract targets various cancers, including triple-negative breast cancer and ovarian cancer.

Eutrema japonica, cancer stem cells, pharmaceutical composition, angiogenesis

Patent

Epitope selection methods

Patent published on the 2026-10-01 in WO under Ref WO2026202772 by BIONTECH SE [DE] (Sahin Ugur [de], Lang Maren [de], Okandan Aylin [de], Vormehr Mathias [de])

Abstract: Presented herein are methods and systems that allow for identification and selection of antigens, e.g., for cancer immunotherapy, such as for inclusion in personalized cancer vaccines (PCVs), use in T-cell therapies, T-cell receptor (TCR)-based therapies, etc.[...]


Our summary: This content discusses methods for identifying and selecting antigens for cancer immunotherapy. It highlights their application in personalized cancer vaccines and T-cell therapies. The focus is on improving therapeutic outcomes through effective epitope selection.

epitope selection, cancer immunotherapy, personalized cancer vaccines, T-cell therapies

Patent

Tropomyosin receptor kinase a (trka) inhibitors and uses thereof

Patent published on the 2026-10-01 in WO under Ref WO2026199075 by UNIV BRITISH COLUMBIA [CA] (Page Brent [ca], Iliev Petar Ilianov [ca], Mccutcheon Conall Robert [ca])

Abstract: Provided herein are compounds of Formula I-III for use in modulating tropomyosin receptor kinase A (TrkA) activity. In particular, the compounds as described herein may have TrkA inhibitory activity. Furthermore, the compounds as described herein may also have multi-kinase inhibitory activity of Janus kinase 2 (JAK2) and/or Proto-Oncogene Tyrosine-Protein Kinase Src (SRC). The compounds as described herein may useful for the treatment of cancer, osteoarthritis (OA), rheumatoid arthritis (RA), in[...]


Our summary: The document discusses compounds that inhibit tropomyosin receptor kinase A (TrkA) and their potential therapeutic uses. These compounds may also inhibit Janus kinase 2 (JAK2) and Src kinases. Applications include treating cancer, osteoarthritis, rheumatoid arthritis, and managing pain and inflammation.

TrkA inhibitors, multi-kinase activity, cancer treatment, inflammation management

Patent

Targeting serotonin transporter (sert) for cancer immunotherapy

Patent published on the 2026-10-01 in WO under Ref WO2026207149 by UNIV CALIFORNIA [US] (Li Bo [us], Yang Lili [us])

Abstract: The invention provides methods for the induction of the serotonin transporter (SERT) gene in solid tumor-infiltrating cytotoxic CD8 T cells. In solid tumors, CD8 T cells secrete serotonin, which stimulates their antitumor reactivities, while SERT functions as a negative regulator by depleting intratumoral serotonin. Discoveries presented herein show that the inhibition of SERT using clinically approved selective serotonin reuptake inhibitors (SSRIs), a popular class of antidepressants, can signi[...]


Our summary: The invention targets the serotonin transporter (SERT) to enhance cancer immunotherapy. Inhibition of SERT in CD8 T cells boosts their antitumor activity. SSRIs show therapeutic synergy with anti-PD-1 therapy and correlate with patient survival in cancers.

serotonin transporter, cancer immunotherapy, CD8 T cells, SSRIs

Patent

Multistage stimuli-responsive nanoparticle platform for intracellular delivery of biologics and drug conjugates thereof

Patent published on the 2026-09-24 in WO under Ref WO2026198863 by LIU QIYONG PETER [US] (Liu Qiyong [us])

Abstract: A multistage, stimuli-responsive nanoparticle platform (TRIDENT) for targeted intracellular delivery of biologic therapeutics is disclosed. The platform comprises an amine-functionalized crosslinked dextran shell on an iron oxide core, with a tunable hydrodynamic diameter of 15-60 nm designed to exceed the renal filtration threshold while enabling tumor accumulation via the EPR effect. Therapeutic payloads — including nanobodies, antibody fragments, peptides, enzymes, and protein-drug conjugat[...]


Our summary: The TRIDENT platform is a multistage, stimuli-responsive nanoparticle system designed for targeted intracellular delivery of biologics. It features a crosslinked dextran shell on an iron oxide core, allowing for tumor accumulation while overcoming renal filtration. The platform enables cytosolic release of therapeutic payloads and supports treatment of heterogeneous tumors.

nanoparticles, intracellular delivery, stimuli-responsive, drug conjugates

Patent

Method for increasing salt tolerance in a crop plant

Patent published on the 2026-09-03 in WO under Ref WO2026181077 by THE DEAD SEA ARAVA SCIENCE CENTER DSASC [IL] (Barak Simon [il], Winters Gidon [il])

Abstract: The invention provides methods for identifying genes associated with plant stress tolerance and producing stress-tolerant crop plants by genome editing. Gene expression profiles under a selected stress are compared between a stress-tolerant plant and a closely related stress-sensitive plant to identify and prioritize candidate regulatory genes, including genes showing constitutively low and/or downregulated "stress-ready" expression in the tolerant plant. Selected homologs or orthologs are edite[...]


Our summary: The method identifies genes linked to salt tolerance in crops. It uses gene expression profiles to find candidate regulatory genes. Genome editing techniques like CRISPR are employed to create stress-tolerant crop plants.

genome editing, stress tolerance, gene expression, CRISPR

Patent

rethinking comprehensive screening in the era of AI

Published on 2026-08-13 by David A. Shaywitz, Nathan D. Price, Daniel K. Sodickson @NATURE npj

Abstract: npj Digital Medicine, Published online: 13 August 2026; doi:10.1038/s41746-026-03106-2Applying advanced measurement technologies proactively in asymptomatic populations predictably yields false positives, as a consequence of Bayes’ Theorem. Yet the same Bayesian arithmetic suggests a remedy: adding context. Serial and multimodal measurements, integrated using context-aware AI that prioritizes within-person change over population norms, can reduce false positive rates while preserving sensitivi[...]


Our summary: The article discusses the impact of advanced measurement technologies on screening asymptomatic populations. It highlights the role of context-aware AI in reducing false positives through serial and multimodal measurements. Challenges such as cost, anxiety, liability, and equity in implementing these technologies are also addressed.

screening, AI, Bayesian, diagnostics

Publication

Glioblastoma-Derived Extracellular Vesicles Modulate &gamma;&delta; T Lymphocytes Through a MIC-Dependent Mechanism

Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI

Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. &amp;gamma;&amp;delta; T lymphocytes are immune cells that can migrate to tumors and induce malignant cells&amp;rsquo; apoptosis. Our previous in silico studies showed that higher &amp;gamma;&amp;delta; T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]


Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.

Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy

Publication

المواضيع المغطاة: Molecular Oncology, genetic alterations, epigenetic alterations, biochemical alterations, high-throughput sequencing, molecular diagnostics, targeted therapeutics, oncogenic pathways, tumor suppressor genes, tumor microenvironment, biomarker discovery, precision medicine, cancer classification, immunomodulation, molecular imaging, translational oncology, clinical applications, peer-reviewed publications, patented innovations ISO 15189, ISO 9001, ISO/IEC 17025, CLSI guidelines, and ASTM E2876..

السياق التاريخي

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(إذا كان التاريخ غير معروف أو غير ذي صلة، على سبيل المثال "ميكانيكا الموائع"، يتم توفير تقدير تقريبي لظهوره الملحوظ)

أحدث الإضافات

أهم المنشورات والمقالات

أفضل الأدوات الأصلية

السنة العاشرة عيد

الصور والتنزيلات بالحجم الكامل متاحة فقط، ومجانية تمامًا، للأعضاء المسجلين.